Kymera Therapeutics, Inc., together with its subsidiary, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, which are in Phase I and IND-enabling respectively. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Period	Debt/Equity
2020-12-31	0.72
2021-12-31	0.32
2022-12-31	0.23
2023-12-31	0.46
2024-12-31	0.17

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KYMR	$85.40	+0.00%	0.69M
3
4
5

Kymera Therapeutics Inc. (KYMR) Debt to Equity Ratio

Debt to Equity Ratio Data

Get Kymera Therapeutics Inc. Data in Excel

More KYMR Financial Data